Boone Capital Management LLC Makes New $12.98 Million Investment in Kymera Therapeutics, Inc. $KYMR

Boone Capital Management LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the second quarter, HoldingsChannel.com reports. The firm bought 113,173 shares of the company’s stock, valued at approximately $12,978,000. Kymera Therapeutics accounts for approximately 3.0% of Boone Capital Management LLC’s portfolio, making the stock its 14th biggest position.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Kymera Therapeutics in the fourth quarter worth $63,000. Finally, Osaic Holdings Inc. raised its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after purchasing an additional 1,083 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Guggenheim increased their price objective on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 price target on shares of Kymera Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price target for the stock from $106.00 to $115.00 in a research report on Monday, July 13th. Mizuho lifted their price objective on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. Finally, Truist Financial boosted their price objective on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $125.65.

Insider Activity at Kymera Therapeutics

In other news, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $76,848,624.72. This represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the transaction, the chief financial officer owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,587,629 shares of company stock valued at $386,183,782 in the last quarter. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Trading Down 0.9%

Shares of NASDAQ KYMR opened at $125.55 on Thursday. The company has a market cap of $10.44 billion, a price-to-earnings ratio of -38.75 and a beta of 1.95. Kymera Therapeutics, Inc. has a 12 month low of $39.84 and a 12 month high of $130.05. The stock has a 50-day moving average price of $111.63 and a two-hundred day moving average price of $93.15.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter in the prior year, the business earned ($0.95) earnings per share. The business’s revenue for the quarter was up 465.2% compared to the same quarter last year. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.75 earnings per share for the current year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.